医学
肝硬化
肝病
丙型肝炎病毒
丙型肝炎
慢性肝病
疾病
病毒
纤维化
抗病毒治疗
肝炎
病毒学
胃肠病学
慢性肝炎
内科学
免疫学
作者
Jinlian Yang,Heping Rao
出处
期刊:PubMed
日期:2018-03-20
卷期号:26 (3): 175-178
标识
DOI:10.3760/cma.j.issn.1007-3418.2018.03.004
摘要
Hepatitis C is one of the major causes of liver disease worldwide. Chronic hepatitis C can cause liver fibrosis and cirrhosis leading to end-stage liver disease. Antiviral therapy can clear the virus, stop the progress of the disease, thereby reducing the incidence of advanced liver disease. This article aims to discuss the effects and safety of antiviral treatments, including direct- acting antiviral agents, on patients with chronic hepatitis C with fibrosis and compensated and decompensated liver cirrhosis.丙型肝炎是全球范围内导致肝脏疾病的主要原因之一。而慢性丙型肝炎会造成肝纤维化及肝硬化,进而发展至失代偿、肝癌等终末期肝脏疾病。抗病毒治疗能够清除病毒,阻止疾病的进展,从而减少晚期肝病的发生。现旨在讨论抗病毒治疗,包括直接抗病毒药物治疗对慢性丙型肝炎肝纤维化及代偿期和失代偿期肝硬化患者的影响及安全性。.
科研通智能强力驱动
Strongly Powered by AbleSci AI